Double Simultaneous Uterotonic Agents Versus Single Agent Regimen to Prevent Early Postpartum Hemorrhage

Recruiting now · Phase 3

Conditions studied: Postpartum Hemorrhage

In brief

To determine the effectiveness of using two medications simultaneously versus one medication, as is standard of care, in preventing early postpartum hemorrhage. There have been studies that looked at giving two medications and that there were reduced odds of postpartum hemorrhage. Specific Aim 1: Determine if double simultaneous uterotonic agent regimen (misoprostol and oxytocin) is superior to single agent (oxytocin only) in reducing postpartum hemorrhage. Specific Aim 2: Determine any potential side effects of a double simultaneous uterotonic agentregimen (misoprostol and oxytocin) versus a single agent (oxytocin only).

Key facts

Study ID

NCT05245227

Run by

Stony Brook University

People needed

1358

Starts

2025-01-27

Expected to finish

2027-01-01

Last updated by the study team

2025-05-04

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: accepted.

You may qualify if…

• All women 18 years and older admitted to delivery at Stony Brook University hospital who agree to participate in the study

You may not qualify if…

• Women under 18 years old
• Women with known coagulation disorders
• Women with planned cesarean hysterectomy
• Women with known placental accreta spectrum disorders
• Women with known allergy to prostaglandins

Where it is running

• Stony Brook University — Stony Brook, New York, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.